Long-term drug survival of tumor necrosis factor inhibitors in patients with rheumatoid arthritis.

CONCLUSION: After >12 months of follow-up, more patients with rheumatoid arthritis receiving etanercept remain on treatment compared with other TNFi. PMID: 31154413 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31154413?dopt=Abstract

Source: J Rheumatol - May 31, 2019 Category: Rheumatology Authors: Emery P, Vlahos B, Szczypa P, Thakur M, Jones HE, Woolcott J, Estrella PVS, Rolland C, Gibofsky A, Citera G, Sockalingam S, Marshall L Tags: J Rheumatol Source Type: research